|Bid||2.00 x 1000|
|Ask||9.75 x 800|
|Day's Range||8.00 - 8.50|
|52 Week Range||3.32 - 9.50|
|Beta (3Y Monthly)||0.49|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
NEW YORK , Jan. 16, 2018 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the fourth quarter 2018 performance ...
Enochian Biosciences, Inc. (“Enochian”) a biopharmaceutical company focused on the development and commercialization of novel therapies for HIV/AIDS and oncology, announced today that the Company’s new Executive Vice-Chair, Dr. Mark Dybul will be taking over the leadership of the Company following the departure of Eric Leire as Chief Executive Officer. Dr. Dybul had previously served as Chair of the Company’s Scientific Advisory Board beginning in August of 2017, and as a director since February of 2018.
A look at the shareholders of Enochian Biosciences Inc. (NASDAQ:ENOB) can tell us which group is most powerful. Insiders often own a large chunk of younger, smaller, companies while huge Read More...
– Appoints former President of GSK Global Vaccine business, Luc Debruyne, to Board of Directors – – Advances ENO-1001 for HIV by entering into research collaboration.
LOS ANGELES, Dec. 03, 2018 -- Enochian Biosciences, Inc. (“Enochian”) (OTCQB: ENOB), a biopharmaceutical company developing potentially curative and preventative gene-modified.